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ABSTRACT 
Pompe disease (PD) is an autosomal recessive muscular disorder caused by deficiency of 
the glycogen hydrolytic enzyme acid α-glucosidase (GAA). The enzyme replacement 
therapy, currently the only available therapy for PD patients, is efficacious in improving 
cardiomyopathy in the infantile form, but not equally effective in the late onset cases with 
involvement of skeletal muscle. Correction of the skeletal muscle phenotype has indeed 
been challenging, probably due to concomitant dysfunctional autophagy. The increasing 
attention to the pathogenic mechanisms of PD and the search of new therapeutic 
strategies prompted us to generate and characterize a novel transient PD model, using 
zebrafish. Our model presented increased glycogen content, markedly altered motor 
behavior and increased lysosome content, in addition to altered expression of the 
autophagy-related transcripts and proteins Beclin1, p62 and Lc3b. Furthermore, the model 
was used to assess the beneficial effects of 3-bromopyruvic acid (3-BrPA). Treatment with 
3-BrPA induced amelioration of the model phenotypes regarding glycogen storage, motility 
behavior and autophagy-related transcripts and proteins. Our zebrafish PD model 
recapitulates most of the defects observed in human patients, proving to be a powerful 
translational model. Moreover, 3-BrPA unveiled to be a promising compound for treatment 
of conditions with glycogen accumulation. 
 
 
 
 
 
 
 
Keywords: Pompe disease, acid α-glucosidase, zebrafish, glycogen, 3-Bromopyruvic acid 
(3-BrPA). 
 
Abbreviations: 3-Bromopyruvic acid (3-BrPA), Hexokinase (HK), 2-(N-(7-nitrobenz-2-
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INTRODUCTION 
 
Pompe disease (PD), also called glycogenosis type II, is an autosomal recessive 
metabolic disorder due to a defect in the lysosomal enzyme acid α-glucosidase (GAA), or 
acid maltase, necessary for glycogen degradation. The defect results in generalized 
excessive glycogen accumulation in tissues, involving in particular skeletal and cardiac 
muscle. 
The spectrum of disease severity encompasses a broad continuum of phenotypes ranging 
from the most severe “classic” form, characterized by child onset, severe cardiomyopathy, 
rapidly progressive course and fatal outcome before two years of age, to the “intermediate” 
infantile form with milder phenotype, to the juvenile and adult forms with prevalent 
involvement of skeletal muscle [1]. The almost total deficiency of the enzyme results in the 
severe infantile form, while partial deficiency is responsible for the intermediate and mild 
forms [2-3]. The enzyme replacement therapy (ERT), the only medication available since 
2006, has represented a major step in the treatment of patients with Pompe disease and, 
although gene therapy is in clinical trial, currently it remains the only FDA-approved 
therapy. ERT has shown to be effective in improving cardiomyopathy in the infantile 
severe Pompe disease form; however, despite clinical benefits for most patients [4-8] the 
late onset cases do not all respond equally well to treatment, and a number of reports 
suggests that correction of the skeletal muscle phenotype is particularly challenging, 
probably due to concomitant altered autophagy [9-12]. However, it remains unclear how 
autophagy, a key molecular mechanism that maintains cellular homeostasis and ensures 
correct macromolecule turnover in the cell [13-15], is responsible for GAA failure to restore 
muscle function, since it is yet unknown if an excessive acceleration or reduction of the 
process is present in Pompe disease. 
The possible role of altered autophagy has stimulated both reassessment of the 
pathogenic mechanisms and investigation of novel therapeutic approaches in Pompe 
disease, including searching for adjunctive and alternative therapies addressing both 
glycogen accumulation and autophagy [16-21]. 
Among the small molecules to be explored for interfering with glycogen accumulation, we 
have developed an interest on 3-bromopyruvate (3-BrPA), an inhibitor of hexokinase (HK), 
which is a key glycolytic enzyme. In vitro and in vivo studies have reported that 3-BrPA is 
an anti-tumor drug effective in those tumor phenotypes in which cancer cells preferentially 
depend on glycolysis to produce adenosine triphosphate (ATP) for growth and proliferation 
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[22-25]. This phenotype, referred to as „aerobic glycolysis‟, was first observed by Warburg 
in 1924. The anti-cancer property of 3-BrPA is due to its ability to inhibit glycolysis, by 
abolishing cell ATP production and, consequently, preventing the hexokinase 
transformation of glucose into glucose-6-phosphate [26], and to trigger activation of the 
autophagic process [27]. 
In mammals, separate genes code for different hexokinase isoforms: HKI, HKII, HKIII, and 
HKIV. HKII is expressed at relatively high levels only in skeletal muscle, adipose tissue, 
and heart. HKII is responsible for the conversion of glucose to glucose-6-phosphate in the 
first step of glycolysis without being regulated by negative feedback (product inhibition) as 
are the other hexokinase isoforms [28]. Furthermore, HKII is reported to be one of 3-
BrPA‟s major targets [29,30] among all the other hexokinase isoforms. 
3-BrPA, having structural similarity with lactate, is likely to be transported across the 
plasma membrane of cells by the proton-linked monocarboxylate transporter (MCTs) [31]. 
Of the 9 known MCT-related sequences in mammals, MCT1 is ubiquitously expressed, but 
is especially prominent in heart and red muscle [32]. 
At present, the best characterized animal model of PD is the GAA-knockout murine model 
which lacks Gaa mRNA transcription and displays a virtually complete acid α-glucosidase 
deficiency [33]. Such a model does not recapitulate the genetics of patients affected by 
late onset Pompe disease, in whom hypomorphic GAA mutations are present [34]. 
In the present study, we generated a novel transient PD model, taking advantage of 
zebrafish, to better recapitulate the pathophysiology of these PD patients. 
Zebrafish, as reported in the literature in the past years, is a suitable model to study 
autophagy [35,36]. Moreover, zebrafish hexokinases isoforms and their proton-linked 
monocarboxylate transporters are very similar and comparable to the mammalian ones 
[37,38], making zebrafish a reliable model for studying 3-BrPA effects. 
In the present study, we characterized the PD zebrafish transient model using two different 
morpholinos (a translation-blocking morpholino, against the start codon ATG and a splice-
blocking morpholino, against a specific portion between intron 9 and exon 10 of the 
zebrafish gaa gene). We investigated the effects of rescuing the resulting phenotypes of 
the latter by injecting an in vitro transcribed gaa RNA. In gaa morphants we assessed 
skeletal muscle condition at optical and electron microscopy level, determined glycogen 
accumulation, and evaluated motor behaviour by touch evoked motility test. Finally, we 
assessed possible beneficial effects of 3-BrPA treatment on glycogen storage, on 
autophagy related transcripts and proteins and on motility behaviour. 
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MATERIALS AND METHODS 
 
Animal care 
Fish were raised and maintained according to good animal practice principles as defined 
by the Italian animal welfare regulations. All experiments were performed on embryos and 
larvae within 5 days post fertilization (dpf), thus not subject to animal experimentation rules 
according to European and Italian directives. 
 
RNA extraction and reverse transcription 
Total RNA was extracted from zebrafish embryos at different stages, from 1 cell stage to 5 
dpf, using TRI Reagent (MRC, Cincinnati, OH, USA). First-strand cDNA synthesis reaction 
from total RNA was catalyzed by Transcriptor First Strand cDNA Synthesis Kit (Roche 
Diagnostic, Penzberg, Germany). cDNA was amplified with specific primers using Phusion 
High-Fidelity polymerase (Finnzymes, Thermo Fisher Scientific, Waltham, MA, USA). The 
PCR products were purified using Illustra ExoProStar (GE Healthcare, Life Sciences, WI, 
USA) and sequenced directly with BigDye Terminator v1.1 Cycle Sequencing Kit (Applied 
Biosystems, Life Technologies, Carlsbad, CA, USA). Sequences were analyzed on an ABI 
Prism 3100 Genetic Analyzer (Applied Biosystems, Life Technologies, Carlsbad, CA, 
USA). The primers used to clone the cDNA in the vector were: gaa: 5′-
ACATCACAGGAAAATGGCGG -3′ (Forward) and 5′-TCCCGTGAACTTGTAACAGC -3′ 
(Reverse). Primers used to visualize I9E10gaa-MO in-frame intron retention were: 5‟- 
CTTTACTTTCGACCCGCAGC -3‟(Forward) and 5‟- AACGGCCGAGTTTTCTTCAC -3‟ 
(Reverse). 
 
Morpholino injections 
Zebrafish gaa was knocked down with two different antisense morpholinos: one, called 
ATGgaa-MO, directed against the translation start site of the gaa transcript, 5′-
CTTCATGTATTAAACACAGGGCTGT-3′, and one, called I9E10gaa-MO, targeting the 
splice site between intron 9 and exon 10, close to the region encoding the catalytic site of 
the Gaa protein, 5′-tgtgattttcttgtttacagGACAT-3′. The latter, in particular, causes retention 
of intron 10, resulting in insertion of 14 aberrant amino acids and in premature stop codon. 
Both morpholinos were designed and purchased, along with a standard control morpholino 
(STD-Ctrl), from Gene Tools (Gene Tools, Philomath, OR, USA).  
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Fertilized eggs, collected after timed mating of adult zebrafish, were injected at the 1-2 cell 
stage using an Eppendorf transferman nk2 micromanipulator (Eppendorf AG, Hamburg, 
Germany). Embryos were injected with either ATGgaa-MO (0.8 pmol/embryo), or 
I9E10gaa-MO (1 pmol/embryo), or STD-Ctrl (to verify absence of morpholino-mediated 
toxicity), diluted in Danieau solution in a volume of 4 nl [39]. To monitor the injection either 
rhodamine dextran (Molecular Probes, Life Technologies, Carlsbad, CA, USA) or phenol 
red (Sigma Aldrich, Saint Louis, MO, USA) were co-injected as tracers and observed 
under a Leica MZ FLIII microscope (Leica Microsystems GmbH, Wetzlar, Germany). 
For rescue experiments, embryos were injected (4 nl total volume) with I9E10gaa-MO plus 
gaa mRNA (10pg). After injection embryos were allowed to develop in fish water at 28 °C 
up to the stage of interest.  
Phenotypic assessment was conducted by visual assessment using a stereomicroscope 
Leica MZ FLIII. Embryo phenotypes were subdivided based on the morphological features 
described in Kimmel et al., 1995 [40]. Deformities included abnormally curled tails, 
shortened body length, abnormal somite structure, etc.  
  
Western Blot 
Dechorionated embryos (minimum 10 per experiment) were boiled for 10 min at 95oC. 
Twenty μg of protein samples were electrophoresed on 10% SDS-PAGE and transferred 
to nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA, USA) following 
standard procedures. The amount of loading proteins was previously determined with 
serial dilutions (10, 20, 50 μg) in order to have bands of adequate intensity to be detected 
within the linear range. ⍺-Tubulin, used as loading control, was also diluted in the linear 
range. The membranes were blocked with 5% nonfat dry milk in TBS, pH 7.5, containing 
0.1% Tween 20 (TBST) for 1 h at room temperature, incubated with antibodies reported in 
Table 2.  
 
Yolk removal 
For sedation Dechorionated embryos were placed, using a plastic pipette, in an eppendorf 
tube (1.5 ml) on ice, for sedation. The embryos were then placed at room temperature 
(RT), as much fluid (fish water/egg water) as possible was removed from the tube, and 
deyolking buffer (1/2 Ginzburg fish Ringer solution) was added (*). The yolks were gently 
removed with a 200 µl pipette tip. The embryos were let floating down to the bottom of the 
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tube, and as much deyolking fluid as possible was removed, 2 rinses with ice cold Ringer‟s 
solution followed with liquid removal each time.  
 (*) Deyolking buffer: 
To obtain 400 ml of deyolking buffer, 0.04 g of NaHCO3 were added to a solution 
composed of 1.3 g NaCl, 0.05 g KCl, 0.06 g CaCl2 or 0.08 g CaCl2 2H2O in 350 ml milliQ 
water, and adjusted to a final volume of 400 ml with further milliQ water. The solution was 
filtered and stored at RT. 
 
Glycogen Assay  
The glycogen amount was determined in dechorionated zebrafish embryos (minimum 10 
per experiment), after yolk removal, by the Glycogen Assay kit II (Abcam, Cambridge, 
England) according to the manufacturer‟s instructions.  
 
Embryo morphological characterization  
Zebrafish at 4 dpf were fixed 2 h in 2.5% glutaraldehyde-sodium phosphate buffer, pH 7.4; 
left in buffer overnight at 4 °C; post-fixed 1 h in 2% phosphate-buffered OsO4, dehydrated 
in graded ethanol, and embedded in epoxy resins (Electron Microscopy Sciences, Hatfield, 
Pennsylvania). Semi-thin sections (1 μm thick) were examined by light microscopy after 
toluidine blue staining. Ultrathin sections of zebrafish tails were collected onto grids, 
stained with uranyl-less (Electron Microscopy Sciences) and Reinold‟s solution, and 
examined with a FEI Tecnai G2 Spirit electron microscope (FEI  Hillsboro, Oregon , United 
States). 
 
Periodic acid–Schiff (PAS) staining 
Resin was removed with sodium methoxide (3‟) from semi-thin sections of 4 dpf zebrafish, 
followed by methanol (5‟) and ethanol (5‟). For staining, sections were placed in: Carnoy 
fixative (15‟); 2% periodic acid (15‟); and Schiff reactive (1 hour in the dark); then they 
were dehydrated and mounted.  
 
LysoTracker Red dye staining 
LysoTracker Red (Thermo Fisher Scientific) was added to embryos at 24 hours post 
fertilization (hpf) in 48-well plates, at a final concentration of 10 μM. The embryos were 
incubated at 28.5°C for 45 minutes. Then, the water was removed and the embryos were 
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rinsed three times with approximately 1 ml fresh fish water immediately before 
fluorescence microscopy imaging, as described [41]. 
 
Glycogen visualization with 2-NBDG 
2-(N-(7-nitrobenz-2-oxa1,3-diazol-4-yl)-amino)-2-deoxyglucose (2-NBDG) was used to 
verify if glycogen could be visualized in vivo. This is a fluorescent synthetic glucose 
analog, hypothetically suitable to be incorporated within the multi-branched polysaccharide 
glycogen chain rendering it fluorescent. Two hundred pg/embryo of 2-NBDG were injected 
into wild type embryos at 1 cell stage. Embryos were examined under an epifluorescence 
microscope at somitogenesis stage and at 24 hpf, and fluorescent glycogen accumulation 
could be detected in the somites and in the tail (Supplementary Figure 1). The limitation of 
this experiment is that 2-NBDG fluorescent signal is visible for about 24 hours, therefore 
only in embryos until 1 dpf. A different approach is thus required to detect glycogen in later 
developmental stages.  
 
Quantification 
To quantify the LysoTracker dye, tricaine treated embryos were observed under an 
epifluorescence microscope and pictures of the entire tail, starting from one somite before 
the end of the yolk, were taken at 10X. The red signal area (expressed as arbitrary units) 
was calculated by means of Fiji softw re (https://imagej.net/Fiji) on images taken at same 
exposure conditions [42]. Using the software, a threshold was applied to the pictures to 
obtain red and black images with regions positive for LysoTracker in red and negative in 
black. The area positive for LysoTracker was calculated as a percentage of the entire 
image, and the mean percentage area was then obtained. The same procedure as before 
was used to quantify the 2-NBDG green signal. 
The quantitation of the western blot bands was performed on membranes from three 
different experiments using Fiji software. To perform the analysis, for each protein and 
loading control, a region of interest (ROI) was defined and saved. The same ROI was 
applied to the other two membranes images, in order to take measurements in the same 
way for the bands and their background. The ratios between protein band of interest and 
loading control band, expressed as arbitrary units, were then exported into an excel file 
and analyzed using Graph-pad Prism software. 
 
qRT-PCR 
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Transcripts of wild-type gaa and of genes related to autophagy were evaluated by qRT-
PCR using primers reported in Table 1. PowerUp SYBR Green Mastermix (Thermofisher) 
and ABI Prism 7000 (Applied Biosystem) PCR systems were used for quantification. ∆∆Ct 
method was used to calculate the relative copies of mRNAs of the gene of interest, 
normalized to the reference gene mRNA (Table 1). 
 
gaa mRNA injection 
The cDNA of full-length zebrafish gaa was amplified by RT-PCR using total RNA extracted 
from whole zebrafish embryos. The primer sequences used were 5′- 
GCAGGATCCCATCGATGGACATCACAGGAAAATGGCGG -3′ (sense primer plus ClaI 
sequence) and 5′- GTTCTAGAGGCTCGAGCCTCCCGTGAACTTGTAACAGC -3′ 
(antisense primer plus XhoI sequence) for zebrafish gaa cDNA. The amplified fragments 
were inserted into pcGlobin2 vector [43]. After digestion of pcGlobin2 vector with 
appropriate restriction enzymes (ClaI and XbaI, New England biolabs, Ipswich, MA; and 
XhoI; Promega Corporation, Madison, WI, USA), the amplified cDNA of gaa was cloned 
into pcGlobin2 vector to obtain the pcGlobin2-gaa construct.  
Plasmids were linearized with XbaI enzyme (New England Biolabs, Ipswich, MA, USA) 
and transcribed using the T7 mMessage Machine kit (Ambion, Life Technologies, 
Carlsbad, CA, USA). Fertilized eggs were injected at the one to two cell stage with 
zebrafish gaa mRNA (10 pg), in a 4 nl volume, using a microinjector (Leica).  
 
3-BrPA treatment 
Different concentrations of 3-BrPA, starting from 20 μM to 2 mM, diluted in 20 ml of fish 
water, were tested, based on published data [44], to evaluate the dose-dependent 
mortality range (Supplementary Figure 2). A concentration of 100 μM was chosen to treat 
the embryos at 60% epiboly stage. Since the 3-BrPA molecule dimension is such that it 
can cross the chorion barrier, the treatment was administered to embryos with chorion. 
 
Screening for embryonic motility 
Larvae were subjected to a tactile stimulus at 3 dpf: using a needle, a gentle stimulus was 
applied to the tail of the zebrafish larvae and their reaction observed (touch-evoked motility 
test) [45]. Upon application of the tactile stimulus wild type larvae at this stage of 
development normally swim away from the source of the stimulus, while embryos injected 
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with morpholino oligonucleotides to knock down genes related to motility show variably 
reduced motility. 
 
Data Analysis 
In all knock down experiments, ATGgaa- and I9E10gaa-MO-injected embryos were 
compared to embryos at the same developmental stage, injected with the same amount of 
a control standard morpholino.  
Results were expressed as means ± standard deviation. Differences between groups of 
morphants in basal conditions (ATGgaa-MO or I9E10gaa-MO vs STD-Ctrl, 3-BrPA-treated 
or non-treated) and differences between groups in rescue experiments (I9E10gaa-MO, 
treated and non-treated, and STD-Ctrl) were assessed by the two-tailed Student T test. P 
values were considered significant: *p ≤ 0.05, **p ≤ 0.01; ***p ≤ 0.001. For graphs, Graph-
pad Prism software was used; for figures, Adobe Photoshop was used. 
 
 
RESULTS 
 
Characterization of the model 
Zebrafish gaa gene  
The gaa zebrafish transcript (variant X1) corresponding to NCBI XM_001921922.5 was 
identified. This is the only full length coding sequence present in zebrafish, located on 
chromosome 3, and reported as the orthologous of the human gene acid alpha 
glucosidase (GAA). The identity between the human GAA and the zebrafish Gaa protein is 
58% (from Genomicus, www.genomicus.biologie.ens.fr/genomicus/cgi-bin/search.pl). This 
good similarity is due to the conservation of all the functional domains (Trefoil domain, 
GH31_N Domain, GH31_MGAM_SI_GAA Domain and Glyco_Hydro_31 Domain) of the 
protein. 
The characterization of gaa expression, performed by qRT-PCR, showed that the gaa 
transcript is present from the first stages of development up to 5 days post fertilization 
(Supplementary Figure 3).  
 
gaa knocked-down embryos displayed phenotypic defects and increased glycogen 
content 
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Both gaa morpholinos were tested at a range of concentrations (from 0.5 pmol/embryo to 
1.5 pmol/embryo) and dose-dependent phenotypic classes were observed. Based on the 
observed phenotypic classes, in order to obtain embryos with glycogen accumulation in 
skeletal muscle, but with an overall conserved somite structure, ATGgaa-MO was injected 
at a concentration of 0.8 pmol/embryo and I9E10gaa-MO at a concentration of 
1 pmol/embryo. Since I9E10gaa-MO injected embryos showed a slight growth delay at 
early stages of development, the phenotypes were examined at 3 dpf. 
ATGgaa-MO injection resulted in reduced Gaa protein amount, as evaluated by western 
blot, (Supplementary Figure 4A), and injection of I9E10gaa-MO causing an out-of-frame 
insertion due to activation of a cryptic splice site (see https://www.gene-
tools.com/choosing_the_optimal_target#blockingnuclearprocessing), resulted in a higher 
aberrant transcript band, as evaluated by RT-PCR, and in lack of the aberrant protein 
band by western blot (Supplementary Figure 4B). 
At the chosen concentrations, of the embryos injected with ATGgaa-MO, 285 (69 % of 
total) pertained to the C1 class with normal-appearing morphology and completely formed 
somites, 95 (23% of total) pertained to the C2 class with partially disrupted somites, and 
36 (8% of total) pertained to the C3 class (Supplementary Figure 5) with unformed or 
totally disrupted somites; whereas, of the embryos injected with I9E10gaa-MO, 225 (53% 
of total) were belonging to the C1 class, 121 (29% of total) to the C2 class, and 74 (18% of 
total) embryos to the C3 class (Figure 1A, B). Of note, in the I9E10gaa-MO morphants 
belonging to the C2 class (121 embryos in total), features such as cardiac edema (in 56 
morphants), enlargement of the IV cerebral ventricle (in 45 morphants) or both alterations 
(in 20 morphants) were observed (Figure 1A). 
In order to evaluate if knock-down of the gaa was recapitulating the human glycogen 
storage condition in skeletal muscle, glycogen amount was measured in ATGgaa-MO and 
I9E10gaa-MO morphants belonging to the C1 class using a commercial glycogen assay 
kit. A significant glycogen increase was observed in ATGgaa morphants (ATGgaa-MO: 
72.25 ± 0.323 vs STD-Ctrl: 43.00 ± 0.204; p<0.0001), compared to control embryos, which 
was even greater in I9E10gaa morphants (I9E10gaa-MO: 122.5 ± 0.540 vs STD-Ctrl: 
43.00 ± 0.204; p<0.0001) (Figure 1C).  
In summary injection of both ATGgaa-MO and I9E10gaa-MO morpholinos caused defects 
in the embryo morphology and an increase in glycogen content, more marked in the latter. 
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Morphological features were altered in muscle and heart of gaa knocked down 
embryos  
Toluidine blue-stained transverse and longitudinal semithin sections of ATGgaa and 
I9E10gaa morphants, at 4 dpf, showed increased space surrounding muscle fibres, often 
occupied by blue violet material, not observed in STD-Ctrl embryos (Figure 1D, upper 
panel). Such blue violet material corresponds to glycogen, which, by Periodic acid–
Schiff (PAS) reaction stains fuchsia (Figure 1D, lower panel). At electron microscopy level, 
increase in glycogen particles, and presence of lysosomal-related elements, such as 
vesicles, electron dense bodies, and small membranous corpuscles, were observed 
around muscle fibres in both ATGgaa and I9E10gaa morphants, more evident in the latter 
(Figure 1E).  
Furthermore, the heart of 4 dpf morphants and control embryos, analyzed at morphological 
level showed increase of blue violet material in pericardial muscles and increase of 
pericardial fluid in I9E10gaa morphants, compared to controls (Figure 1F). Moreover, 
morphant‟s heart revealed laxity of the ventricle and augment of the cardiac jelly layer 
(Figure 1F, b‟‟), compared to the control embryo heart. 
In summary, in both morphants glycogen appeared increased by PAS and toluidine blue 
staining; glycogen particle increase and lysosomal-related elements were observed by 
electron microscopy; and morphological defects were found in the heart. 
 
Motility was defective in gaa knocked down embryos 
The touch evoked response test was performed on ATGgaa and I9E10gaa morphants 
belonging to the C1 class at 3 dpf. In comparison to STD-Ctrl-injected embryos, a slight 
escape attempt was present in 21 ATGgaa morphants out of 30, with evident muscle 
stiffness. Motility defects were more severe in I9E10gaa morphants: 26 injected embryos 
out of 30 showed very weak escape contraction, and obvious muscle stiffness 
(Supplementary Videos 1 and 2).  
 
Lysosomal content was more increased in ATGgaa than in I9E10gaa morphants  
To track lysosomes in vivo, LysoTracker dye was added to ATGgaa-MO-, I9E10gaa-MO-
and STD-Ctrl-MO-injected embryos at 24 hpf. All embryos had been previously injected 
with 2-NBDG at one cell stage. 2-NBDG, a D-glucose fluorescent derivative used to 
monitor glucose incorporation into glycogen [46], was used to label glycogen in vivo.  
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Quantitation of the LysoTracker red signal showed that ATGgaa morphants had a 
significant red signal increment compared to STD-Ctrl (ATGgaa-MO: 12360 ± 3195 vs 
STD-Ctrl: 5154 ± 885.8; p=0.0289), while I9E10gaa morphants displayed a red signal 
comparable to STD-Ctrl (I9E10gaa-MO: 6070 ± 837.0 vs STD-Ctrl: 5154 ± 885.8; 
p=0.4588) (Figure 1G).  
Quantitation of the 2-NBDG green signal showed a significant increase in the green dot 
area in both gaa morphants, compared to STD-Ctrl (ATGgaa-MO: 5261 ± 702.7 vs STD-
Ctrl: 3300 ± 377.0; p= 0.0200; I9E10gaa-MO: 6077 ± 851.9 vs STD-Ctrl: 3300 ± 377.0; 
p=0.0023) (Figure 1H). 
Tracking in vivo of lysosomes and glycogen by fluorescent dyes showed increase in 
lysosomes only in ATGgaa morphants, while glycogen was increased in both. 
 
Expression of autophagy-related transcripts and proteins was altered in I9E10gaa 
morphants 
At 48 hpf, atg7, atg4, beclin1, mtor, p62, lc3b and ulk1 transcript levels by qRT-PCR were 
not significantly different in ATGgaa morphants compared to STD-Ctrl embryos (not 
shown). In I9E10gaa morphants a significant increase in lc3b (I9E10gaa-MO: 2.284 ± 
0.297 vs STD-Ctrl: 0.9998 ± 0.225; p=0.0138) and beclin1 transcript levels (I9E10gaa-MO: 
2.259 ± 0.301 vs STD-Ctrl: 1.015 ± 0.102; p=0.0078) was observed, compared to STD-Ctrl 
(Figure 2A). 
Proteins related to autophagy Lc3, p62, mTOR, p-mTOR, AMPk, p-AMPk, Lamp2 and 
Beclin1, quantitated on Western blot bands, at 24 hpf, were not significantly different in 
both morphants compared to STD-Ctrl embryos (Supplementary Figure 6); whereas, in 
I9E10gaa morphants, at 4 dpf, p62 (I9E10gaa-MO: 1.037 ± 0.2109 vs STD-Ctrl: 0.2733 ± 
0.05925; p=0.0252) and Lc3b (measured as ratio Lc3bII/Lc3bI) (I9E10gaa-MO: 1.790 ± 
0.01155 vs STD-Ctrl: 0.8600 ± 0.05568; p<0.0001) were significantly increased compared 
to STD-Ctrl (Figure 2B). 
In summary, among autophagy-related transcripts and proteins, lc3b and beclin1 mRNA 
levels were significantly increased at 48hpf, and p62 and Lc3b proteins were significantly 
increased at 4dpf in I9E10gaa, but not in ATGgaa morphants. 
 
gaa mRNA injection rescued Pompe disease phenotype in I9E10gaa morphants 
To avoid base-pairing between the oligomer and the in vitro synthetized mRNA that could 
occur with ATGgaa morpholinos, the rescue experiment was performed exclusively in 
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I9E10gaa morphants (hereinafter called rescued I9E10gaa morphants). One-cell stage 
embryos were co-injected with I9E10gaa-MO (1 pmol/embryo) and 10pg/4nL gaa mRNA. 
The resulting phenotypes were compared with I9E10gaa morphants and with STD-Ctrl 
embryos and the distribution of the phenotypes, based on the correct formation of somites, 
was annotated at 24 hpf (Figure 3A). To classify the phenotypes, correct morphology 
(Figure 3Ba), developmental delay (Figure 3Bc) and deformities (Figure 3Be) were 
considered. The rescued morphants presented a significant increase in the number of 
embryos with correct morphology, compared to non-rescued I9E10gaa-MO (I9E10gaa-MO 
+ gaa mRNA: 14.80 ± 1.158 vs I9E10gaa-MO: 6.200 ± 0.8602; p=0.0003). No significant 
differences were observed in growth retardation between rescued and non-rescued 
I9E10gaa morphants; while deformities were significantly less in rescued I9E10gaa 
morphants compared to non-rescued (I9E10gaa-MO + gaa mRNA: 5.0 ± 0.3162 vs 
I9E10gaa-MO: 12.60 ± 2.379; p=0.0133) (Figure 3B, C).  
The embryos were then let develop in fresh fish water and again observed at 48 hpf. At 
this developmental stage, although the I9E10gaa morphants presented fewer 
morphological defects, rescued morphants still showed significantly higher numbers of 
embryos presenting an appropriate body and somite formation (Figure 3Bb) (I9E10gaa-
MO + gaa mRNA: 18.20 ± 2.672 vs I9E10gaa-MO: 10.40 ± 1.860; p=0.0435). Numbers of 
morphants with growth retardation (Figure 3Bd) or deformities (Figure 3Bf) were not 
significantly different between rescued and non-rescued morphants at this developmental 
stage. Rescued morphants presenting cardiac edema, enlargement of the IV cerebral 
ventricle or both, were fewer than non-rescued morphants, but, again, the difference was 
not significant. 
Rescue with gaa mRNA on glycogen storage was assessed by the glycogen assay kit at 
48 hpf. The amount of glycogen (ng/μl) was significantly less in I9E10gaa rescued 
morphants, compared to non-rescued I9E10gaa-MO morphants (I9E10gaa-MO + gaa 
mRNA: 143.6 ± 0.731 vs I9E10gaa-MO: 155.3 ± 2.186; p=0.0071) (Figure 3D). 
In summary, the rescue experiment showed that embryos with correct morphology were 
more than non rescued embryos at 24 hpf, and at 48 hpf, although at the latter stage 
growth retardation or deformities did not differ. Glycogen amount was also significantly 
less in rescued morphants. 
 
3-Bromopyruvate (3-BrPA) treatment 
3-BrPA enhanced motility behavior in gaa morphants 
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The touch evoked response test, performed at 3 dpf on 3-BrPA-treated ATGgaa and 
I9E10gaa morphants, showed an improvement of escape contractions in both morphants 
(I9E10gaa-MO: n=20/30; ATGgaa-MO: n=24/33) compared to untreated morphants 
(n=30/30) (Supplementary Video 3 and Supplementary Figure 8). 
 
3-BrPA improved muscle morphology in morphants 
In transverse and longitudinal semi thin sections of ATGgaa and I9E10gaa morphants at 4 
dpf treated with 3-BrPA, the space surrounding muscle fibres appeared either reduced 
compared to untreated morphants, as shown in toluidine blue-stained semi thin sections 
(Figure 4A, D) or devoid of positive fuchsia material, as shown in PAS-stained sections 
(Figure 4B, E).  
At the electron microscopy level reduction in glycogen particles and presence of empty 
spaces around fibres was observed in both ATGgaa and I9E10gaa 3-BrPA-treated 
morphants (Figure 4C, F).  
 
3-BrPA increased lysosomal content in morphants  
Quantitation of LysoTracker (Figure 5A) red signal showed a significant increase in the red 
signal in ATGgaa morphants treated with 100 µM 3-BrPA, compared to untreated 
ATGgaa-MO (ATGgaa-MO + 3-BrPA: 45910 ± 8922 vs ATGgaa-MO: 12360 ± 3195; 
p=0.0011), as well as in I9E10gaa-MO treated morphants compared to untreated 
(I9E10gaa-MO + 3-BrPA: 15590 ± 3575 vs I9E10gaa-MO: 6070 ± 837.0; p=0.0175) 
(Figure 5B). 
Quantitation of 2-NBDG showed in both 3-BrPA-treated morphants a significant decrease 
in the signal compared to untreated morphants (ATGgaa-MO + 3-BrPA: 3300 ± 377.0 vs 
ATGgaa-MO: 5261± 702.7; p=0.0200; I9E10gaa-MO + 3-BrPA: 2470 ± 217.2 vs 
I9E10gaa-MO: 6077 ± 851.9; p<0.0001) (Figure 5C).  
Tracking in vivo of lysosomes and glycogen by fluorescent dyes showed an increase in 
lysosome content and a decrease in glycogen in both morphants after 3-BrPA treatment. 
 
3-BrPA treatments improved rescue in I9E10gaa morphants 
3-BrPA treatments were assessed after rescue in I9E10gaa morphants as the rescue 
experiment was carried out only in those embryos. At 24 hpf a significant increase in the 
number of embryos presenting with correct morphology was observed in morphants 
rescued with gaa mRNA and treated with 3-BrPA compared to untreated and rescued 
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morphants (I9E10gaa-MO + mRNA + 3-BrPA: 25.670 ± 1.856 vs I9E10gaa-MO + mRNA: 
15.00 ± 2.082; p=0.0187); or compared to untreated morphants (I9E10gaa-MO + mRNA + 
3-BrPA: 25.670 ± 1.856 vs I9E10gaa-MO: 7.333 ± 0.882; p=0.0009). Furthermore, the 
number of embryos presenting correct morphology was increased in I9E10gaa-MO + 3-
BrPA compared to I9E10gaa-MO embryos (I9E10gaa-MO + 3-BrPA: 16.00 ± 2.082 vs 
I9E10gaa-MO: 7.333 ± 0.8819; p=0.0186) (Figure 6Aa, Ab).  
Numbers of embryos showing growth retardation were not significantly different between 
groups (I9E10gaa-MO, rescued I9E10gaa-MO, and rescued I9E10gaa-MO + 3-BrPA). In 
the rescued morphants treated with 3-BrPA, those carrying deformities were significantly 
fewer than in the non-rescued and untreated morphants (I9E10gaa-MO: 11.67 ± 1.202 vs 
I9E10gaa-MO + mRNA + 3-BrPA: 3.667 ± 1.856; p=0.0224), but similar to the rescued 
morphants (I9E10gaa-MO + mRNA + 3-BrPA: 1.667 ± 0.8819 vs I9E10gaa-MO + mRNA: 
2.333 ± 1.856; p=0.7619). The embryos treated with 3-BrPA alone presented a significant 
lower number of embryos carrying deformities than I9E10gaa morphants (I9E10gaa-MO + 
3-BrPA: 4.667 ± 0.3333 vs I9E10gaa-MO: 11.67 ± 1.202; p=0,0050) (Figure 6Ac). 
At 48 hpf, the number of morphants with correct morphology was significantly higher in the 
rescued morphants and 3-BrPA-treated compared to untreated and rescued morphants 
(I9E10gaa-MO + mRNA + 3-BrPA: 33.00 ± 3.215 vs I9E10gaa-MO + mRNA: 18.67 ± 
3.667; p=0.0424), or compared to untreated and non-rescued morphants (I9E10gaa-MO + 
mRNA + 3-BrPA: 33.00 ± 3.215 vs I9E10gaa-MO: 11.00 ± 2.646; p=0.0062) (Figure 6Bb). 
Differences in growth retardation and in deformities were not significant between groups at 
48 hpf (Figure 6Ad, Af). 
3-BrPA treatment of rescued I9E10gaa morphants significantly reduced numbers of 
embryos presenting cardiac edema and hindbrain IV ventricle enlargement, at 48 hpf, 
compared to untreated morphants (Figure 6B,C). In particular, in rescued and 3-BrPA-
treated morphants, numbers of embryos presenting cardiac edema were significantly 
fewer (2,2%, n=78) than in untreated and non-rescued morphants (20,3%, n=59); 
moreover, hindbrain enlargement was totally absent (0%, n=78) compared to untreated 
and non-rescued morphants (7,5%, n=59). Moreover, morphants treated with 3-BrPA 
alone showed a significant decrease (2,7%, n=62) in embryos percentage presenting 
cardiac edema and hindbrain IV ventricle enlargement, compared to untreated and non-
rescued morphants (20,3%, n=59). 
3-BrPA treatment of rescued I9E10gaa morphants did not change glycogen amount, at 48 
hpf, compared to untreated and rescued I9E10gaa morphants (I9E10gaa-MO + mRNA + 
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3-BrPA: 139.2 ± 0.441 vs I9E10gaa-MO + mRNA: 143.6 ± 0.731; p=0.064). The 3-BrPA 
treatment alone reduced glycogen amount significantly, compared to the glycogen present 
in I9E10gaa morphants (I9E10gaa-MO + 3-BrPA: 0.1420 ± 0.001528 vs I9E10gaa-MO: 
0.1487 ± 0.001202; p=0,0265) (Figure 6D). 
In summary, 3-BrPA treatment improved the overall morphology and the cardiac edema in 
I9E10gaa morphants either alone or in addition to rescue. The rescue of I9E10gaa 
embryos reduced glycogen amount, in a comparable manner to 3-BrPA treatment. 
 
3-BrPA treatment modified the expression of Beclin1, p62, and Lc3b transcripts and 
proteins  
3-BrPA treatment did not significantly change atg7, atg4, mTor, p62, lc3b or ulk1 
transcripts levels in ATGgaa morphants and STD-Ctrl embryos compared to untreated.  
3-BrPA-treatment significantly increased transcript levels of lc3b (I9E10gaa-MO + 3-BrPA: 
3.298 ± 0.1572 vs I9E10gaa-MO: 2.284 ± 0.2973, p=0.0235), and p62 (I9E10gaa-MO + 3-
BrPA: 5.593 ± 0.6959 vs I9E10gaa-MO: 1.009 ± 0.07910, p=0.0006), and significantly 
decreased transcript levels of beclin1 (I9E10gaa-MO + 3-BrPA: 0.3567 ± 0.2024 vs 
I9E10gaa-MO: 1.024 ± 0.1364, p=0.0357) in I9E10gaa morphants compared to untreated 
I9E10gaa morphants (Figure 7A). 
A significant decrease in beclin1 mRNA level was also observed in 3-BrPA-treated STD-
Ctrl embryos compared to untreated STD-Ctrl embryos (STD-Ctrl + 3-BrPA: 0.341 ± 0.04 
vs STD-Ctrl: 1.015 ± 0.102; p=0.0008). 
3-BrPA-treatment significantly decreased Beclin1 protein amount in I9E10gaa morphants 
compared to untreated I9E10gaa morphants (I9E10gaa-MO: 0.9767 ± 0.1014 vs 
I9E10gaa-MO + 3-BrPA: 0.4833 ± 0.04096; p=0.0107).  
3-BrPA-treatment significant increased p62 protein amount (STD-Ctrl + 3-BrPA: 0.6133 ± 
0.01202 vs STD-Ctrl: 0.2733 ± 0.05925; p=0.0049) and significantly decreased Lc3b 
(STD-Ctrl + 3-BrPA: 1.117 ± 0.06489 vs STD-Ctrl: 0.8600 ± 0.05568; p=0.0399) in STD-
Ctrl embryos compared to untreated STD-Ctrl (Figure 7B). 
3-BrPA treatment main effect was an increase in p62 and a decrease in beclin1 mRNA 
levels and Beclin1 protein amount in I9E10gaa morphants. It also induced a decrease in 
beclin1 mRNA, and an increase in p62 and decrease in Lc3b protein amount in STD-Ctrl. 
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DISCUSSION 
 
Currently, the standard of care for Pompe disease patients is ERT which is efficacious in 
improving cardiomyopathy but not equally effective in cases with involvement of skeletal 
muscle: therefore, improved or supplementary therapeutic strategies are needed.  
In our study, we have generated and characterized a new transient Pompe disease 
zebrafish model aimed at testing novel potential remedies for this pathology. 
Taking advantage of two different morpholinos, one directed against the translation start 
site of the gaa transcript, and one targeting the splice site between intron 9 and exon 10, 
close to the catalytic site of the protein, we obtained the ATGgaa morphants, expressing 
low amount of the Gaa protein, and the I9E10gaa morphants, in which an aberrant gaa 
transcript and protein is present. Such aberrant protein, of theoretically lower molecular 
weight (57-58 kDa, compared to circa 70 kDa WT), was not detected by western blot. We 
presume that this truncated form deriving from the translation of the aberrant mRNA with 
intron retention in I9E10gaa morphants, acts as a dominant negative. Although the 
aberrant cDNA is clearly visible, as shown in Supplementary Figure 4B, the anti-Gaa 
antibody cannot possibly detect a truncated version of the protein, as the only conserved 
epitope in zebrafish is located at the C-terminus of the protein. 
Our extensive investigation shows that several pathological characteristics recapitulate 
Pompe disease features [47] in both models, but especially in the I9E10gaa-MO-injected 
embryos. 
We found an increase in glycogen content, detected using two different methods: one 
based on injection of 2-NBDG, that allows visualization of the glucose flux in 24 hpf 
zebrafish embryos by fluorescence microscopy analysis [48]; and one based on 
colorimetric analysis with a commercial assay kit tailored to our animal model. Both 
approaches showed a significant increment in glycogen amount in Pompe disease 
zebrafish knockdown models, more evident in the I9E10gaa morphants. The increment 
was rescued by co-injection with gaa mRNA confirming that Gaa deficiency was the cause 
of glycogen increase. These data were confirmed also by the morphological studies at 
optical and ultrastructural level. 
We observed heart edema in almost half of the embryos among the I9E10gaa morphants 
at 48 hpf, that we associated with the Pompe disease phenotype. This was confirmed by 
the morphological analysis of the heart of 4 dpf glutaraldehyde-fixed morphants and 
control embryos. In I9E10gaa morphants, compared to controls, we observed 
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an increase in glycogen surrounding the pericardial muscles fibers and an increased 
amount of fluid in the pericardial cavity (edema), likely caused by the malfunction of the 
pericardial muscles. Moreover, morphants showed an abnormal deposition of the cardiac 
jelly layer, located between endocardium and myocardium [49]. Cardiac failure is the main 
cause of death in untreated classic infantile Pompe disease, but is also a characteristic of 
some late onset Pompe disease patients [50]. Edema of the heart, in some cases, has 
been associated to off target effects of morpholino in zebrafish. However, in our model, the 
edema was proportionate to the severity of the phenotypes and, importantly, gaa 
reintroduction during the rescue experiment ameliorated this particular aspect confirming 
that Gaa deficiency was the exclusive cause of the edema.  
Furthermore, we observed reduced morphant motility, more marked in the I9E10gaa 
morphants, due to altered functionality of embryo muscles. This aspect was recovered 
during the rescue experiment, again confirming that Gaa deficiency, with consequent 
increment of glycogen storage, was the cause of the failed touch evoked response test. 
Finally, in our knockdown model, we also found altered expression of autophagy-related 
components. In particular, we observed an increase in lysosomal corpuscles at 
ultrastructural level, a significant increase in lysosomal content (by LysoTracker staining), 
and a significantly increased expression of autophagy-related transcripts and proteins, 
with some differences between the two morphants.  
The wide spectrum of Pompe disease is indeed attributed to altered autophagic flux, 
although it remains unclear how, since it is yet unknown if an excessive acceleration or 
reduction of this process is present. In addition to being involved in degradation, 
autophagy plays an important part in inflammation and pathogen clearance, and is 
implicated in cellular architectural changes that occur during differentiation and 
development [51]. Since autophagy is a fundamental evolutionarily conserved mechanism, 
and zebrafish development is strongly connected with it [35,52], we associated the 
developmental retardation, more evident in our I9E10gaa morphants, to altered autophagy 
[53]. Indeed, we observed significant changes in beclin1 and lc3b transcript levels and in 
p62 and Lc3b protein levels in the I9E10gaa morphants. All these proteins are involved in 
early stages of autophagy: Beclin1 is an autophagy regulator involved in the formation of a 
double-membrane structure that engulfs cytoplasmic material to form the autophagosome 
[54], Lc3b is related to the crescent-shaped double membrane tightly associated to 
Beclin1, and p62 facilitates ubiquitinated protein degradation by linking the ubiquitin–
proteasome system to the autophagy pathway [55]. The lack of correlation between 
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protein levels and mRNA expression is not surprising given that multiple processes 
contribute to the expression level of a protein [56]. 
All together our data confirm that knocking down or inducing the insertion of intron 10 in 
the gaa transcript in zebrafish, recapitulate most aspects of the human Pompe disease 
condition, which are more evident in the I9E10gaa morphants. 
Remarkably, the zebrafish Pompe disease knockdown model, allowed us to evaluate the 
effects of 3-BrPA in vivo. This compound has never been tested before for Pompe 
disease. Since the main action of this compound is the inhibition of the key glycolytic 
enzyme HKII, a key regulator of glycolysis through autophagy [57], we hypothesized that 
3-BrPA could potentially modulate glycogen accumulation and autophagy in Pompe 
disease muscle. The beneficial, but also toxic effects of this compound have been known 
in the last 10 years in particular for the treatment of glycolysis-dependent tumors [58,59]. 
In cancer cells, 3BrPA can accomplish its deleterious effect thanks to their high expression 
of monocarboxylate transporters and exacerbation of glycolytic metabolism [60]; however, 
3-BrPA is slightly toxic to cells due to ROS production [61].  To limit such potential adverse 
effect, we used 3-BrPA at a concentration (100 µM) that was one-twentieth the 
concentration (2 mM) identified as LD50.  
We observed an improvement in morphants motility after 3-BrPA administration, which we 
interpreted as due to an improved functionality of embryo muscles, consistent with the 
decrease in glycogen storage. These data were confirmed also by the morphological 
studies at optical and ultrastructural level. In addition to its positive action in the I9E10gaa 
morphants, 3-BrPA enhanced the effect of the rescue experiment on glycogen storage, 
cardiac edema and hindbrain enlargement. Such result suggests that 3-BrPA can correct 
some of the phenotypic changes seen in the Pompe disease model and could be an 
adjuvant therapy in combination with ERT since the rescue experiment could mirror in 
some way the enzymatic replacement therapy.  
Furthermore, 3-BrPA treatment induced changes in autophagy-related transcripts and 
proteins. To this regard, a major result of the treatment was the reduction in Beclin1 
transcript and protein, since Beclin1 is central in the early formation of autophagosomes. A 
reduced nucleation, consequent to Beclin1 decrease, would produce fewer 
autophagosomes. The subsequent increase in Lc3b and p62 levels instead, is probably 
related to a slow down of the autophagic flux and to an increment in size of the 
autophagosomes.  
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We also observed an increment in red dots in the LysoTracker dye experiment in 
I9E10gaa morphants after 3-BrPA treatment, resulting in an increase in lysosomes, 
compared to untreated morphants. 3-BrPA is likely to induce a mild status of starvation 
that would activate the transcription factor EB (TFEB), the lysosomal biogenesis 
transcription factor, thereby increasing lysosomal activity (acidification and delivery of 
hydrolases) and trafficking (autophagosome - lysosome fusion) in strict correlation with 
autophagy [62].  
In conclusion, we characterized for the first time a Pompe disease transient model in 
zebrafish that recapitulates most of the defects observed in human patients and reflects 
the genetic condition of most Pompe patients, in which the GAA is dysfunctional, but not 
totally absent.  
This model thus has proven to be a suitable, rapid and low cost tool both for investigating 
pathogenic mechanisms of Pompe disease and for testing compounds with therapeutic 
potential. To this regard we have demonstrated, as proof of principle, that 3-BrPA has 
beneficial effects in the zebrafish Pompe disease model, since it reduces the glucose 
entrance in muscle cells and modulates the autophagy flux, without creating a problematic 
condition of starvation. Additional studies will be needed in a stable zebrafish mutant to 
explore 3-BrPA treatment for a long period of time. The present study is in fact preparatory 
to the development of a stable zebrafish PD model. In such model the catalytic site of the 
Gaa protein will be disrupted to better reproduce the pathological features of PD, keeping 
in mind that a compensation of the pathological phenotype could occur in adult stages, as 
already reported [63]. 
Our new zebrafish PD model, will simplify testing novel drugs with therapeutic potential, as 
3-BrPA, reducing timing and costs of the screening. Moreover, this translational model, 
that recapitulates better the patient conditions, will accelerate further investigations that 
underlies glycogen storage conditions.  
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Figure 1. 
 
gaa zebrafish morphants recapitulate the human Pompe disease phenotype. (A) 
Classes of phenotypes shown for the I9E10gaa-injected embryos (C1, C2 and C3). In 
morphants belonging to class C2, features such as cardiac edema (red asterisk), 
enlargement of the IV cerebral ventricle (black arrowhead) or both alterations are visible. 
Morphants of the class C1 appear normal, while those of class C3 show disrupted 
morphology. Scale bar = 300 μm. (B) Percentages of classes obtained with ATGgaa and 
I9E10gaa morpholinos injections. (C) Glycogen amount measured by the Glycogen Assay 
kit II in ATGgaa-MO and I9E10gaa-MO morphants pertaining to the C1 class. Results 
were achieved from 4 independent experiments, each using 10 embryos pulled together, 
for a total of 40 embryos per group. (D, upper panel) Toluidine blue-stained transverse 
semithin sections of I9E10gaa morphants showing increased spaces surrounding muscle 
fibres (black arrows), not observed in STD-Ctrl embryos. Scale bar = 20 µm. (D, lower 
panel) PAS staining on transverse semithin sections of STD-Ctrl embryo, compared to 
I9E10gaa morphant at 4 dpf. Glycogen detected in spaces surrounding muscle fibers 
(black arrows) is increased and more visible in morphants, compared to controls. Scale 
bar = 2µm. (E) Electron micrographs showing increase in glycogen (black arrows) and 
lysosomal corpuscles (white arrowheads) in I9E10gaa morphants, but not in STD-Ctrl 
embryos. Scale bar = 2µm. (F) Toluidine blue-stained transverse semithin sections of 
STD-Ctrl embryo heart (a) compared to I9E10gaa morphant heart (b) at 4 dpf. Increased 
spaces surrounding pericardial muscle fibres (black arrows) and lipid droplets (black 
arrowhead) are present in morphants, but not in controls (b’). Moreover, an augment of the 
cardiac jelly layer (white arroheads) is observed in the morphant heart (b’’), with the 
presence of an increased cardiac fluid (asterisks) (b). Scale bar = 100 µm. (G) 
Quantitation of the LysoTracker red signal; and (H) of the 2-NBDG green signal in both 
morphants and in STD-Ctrl. Results were achieved from 5 independent experiments each 
using 25 ATGgaa morphants, 25 I9E10gaa morphants and 25 STD-Ctrl embryos. 
 
Figure 2. 
Expression of autophagy related transcripts and proteins. (A) beclin1 and lc3b 
transcript levels at 48 hpf. Results were achieved from 5 independent experiments each 
using cDNA obtained after RNA extraction from 10 embryos pulled together, for a total of 
50 embryos. (B) Representative western blot showing Beclin1, p62 and Lc3b protein 
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bands; and their quantitation (average of 3 gels) at 4 dpf, in I9E10gaa morphants 
compared to STD-Ctrl.  
 
Figure 3. 
Rescue of I9E10gaa morphants phenotype. (A) Classes of phenotypes obtained at 24 
hpf after co-injection of I9E10gaa-MO (1 pmol/embryo) and 10pg/4nL gaa mRNA. (B) 
Graphs reporting average numbers of embryos with correct morphology (a, b), 
developmental delay (c, d) and deformities (e, f) at 24 hpf and 48 hpf. The total number of 
embryos per group were: n=59 I9E10gaa-MO, n=73 rescued I9E10gaa-MO, n=78 3-BrPA 
rescued I9E10gaa-MO, n=62 I9E10gaa-MO plus 3-BrPA, n=60 STD Ctrl. (C) 
Representative phenotypes of STD-Ctrl, I9E10gaa-MO and I9E10gaa rescued embryos, at 
2 dpf, with cardiac edema (black asterisks) and enlargement of IV hindbrain ventricle 
(white asterisks) more evident in I9E10gaa morphants. Scale bar = 200 µm. (D) Evaluation 
of glycogen amount in I9E10gaa morphants before and after rescue, compared to STD-
Ctrl, at 48 hpf. Results were achieved from 4 independent experiments, each using 10 
embryos pulled together, for a total of 40 embryos. 
 
Figure 4. 
Effect of 3-BrPA treatment on muscle morphology. (A, D) Toluidine blue- and (B, E) 
PAS-stained transverse semi thin sections of I9E10gaa-MO embryos at 4 dpf, showing 
that, after 3-BrPA treatment, spaces surrounding muscle fibres (arrows) appear either 
reduced or devoid of positive fuchsia material around muscle fibres. Scale bars = 20 µm. 
(C, F) Electron micrographs showing that glycogen particles (black arrows) present in 
I9E10gaa morphants (C), appear decreased after 3-BrPA treatment (F), while empty 
spaces around fibres (black arrowheads) appear increased. Lysosomal corpuscles (white 
arrowheads) are visible in untreated I9E10gaa morphants . Scale bar = 2µm. 
 
Figure 5. 
3-BrPA treatment effect on lysosomes. (A) Fluorescence images showing LysoTracker 
and 2-NBDG signals in STD-Ctrl (a-c), ATGgaa-MO injected embryos (d-f), ATGgaa-MO 
3-BrPA-treated embryos (g-i), I9E10gaa-MO injected embryos (j-l), I9E10gaa-MO 3-BrPA-
treated embryos (m-o). Scale bar = 100 µm. (B, C) Quantitation of LysoTracker and 2-
NBDG signal in ATGgaa and I9E10gaa morphants before and after 3-BrPAtreatment, and 
in STD-Ctrl embryos. The LysoTracker dye and 2-NBDG assessment was performed in 23 
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zebrafish embryos per group (115 embryos in total), obtained from 5 independent 
experiments. 
 
Figure 6. 
3-BrPA treatment effect on rescue experiment. (A) Graphs reporting average numbers 
of embryos with correct morphology (a, b), developmental delay (c, d) and deformities (e, 
f) at 24 hpf and 48 hpf, showing improvement of phenotypes after 3-BrPA-treatment in 
embryos either rescued or non rescued. The total number of embryos per group were: 
n=59 I9E10gaa-MO, n=73 rescued I9E10gaa-MO, n=78 3-BrPA rescued I9E10gaa-MO, 
n=62 I9E10gaa-MO plus 3-BrPA, n=60 STD Ctrl. (B, C) Percentages of I9E10gaa 
morphants presenting cardiac edema or hindbrain IV ventricle enlargement after rescue, 
after rescue plus 3-BrPA treatment, and after 3-BrPA alone. The total number of embryos 
per group were: n=59 I9E10gaa-MO, n=73 rescued I9E10gaa-MO, n=78 3-BrPA rescued 
I9E10gaa-MO, n=62 I9E10gaa-MO plus 3-BrPA. (D) Glycogen amount in I9E10gaa 
morphants, after rescue, after rescue plus 3-BrPA treatment, and after 3-BrPA alone. 
Results were achieved from 4 independent exp riments, each using 10 embryos pulled 
together, for a total of 40 embryos per group. 
 
Figure 7. 
Effects of 3-BrPA on autophagy-related transcripts and proteins in I9E10gaa 
morphants.  
(A) beclin1, p62 and lc3b transcript levels; and (B) representative western blot showing 
Beclin1, p62 and Lc3b protein bands; and their quantitation (average of 3 gels) at 4 dpf, in 
in I9E10gaa morphants and STD-Ctrl embryos before and after 3-BrPA treatment. Results 
were achieved using cDNA obtained after RNA extraction from 10 embryos pulled 
together, collected during 5 independent experiments, for a total of 50 embryos.  
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Table 1. 
Transcripts of genes related to autophagy were evaluated by qRT-PCR using primers 
reported in table 1, normalized to the reference gene mRNA (housekeeping gene). 
 
Table 2. 
List of primary and secondary antibodies used for the experiments described. Antibodies 
name, dilution used, catalog number and Lot number (where available) were included. 
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Table 1 
Primers: 
 
gaa-Forward 
 
5'-AGTCAGCGAGCCCAGGAT-3' 
 
gaa-Reverse 
 
     5'-CCAACGAAGCAGGAAACA-3' 
atg4b-Forward 
 
5‟-ACACCACTCAGCCAGCAG-3‟ 
atg4b-Reverse  5‟-AAGCCAGCAGCAATAGAAGG-3‟ 
beclin1-Forward 5‟-GCCATTGTATTGTTCAGGTG-3‟ 
beclin1-Reverse 5‟-CAGAAGCCAGTGTCATCC-3‟ 
atg7-Forward 5‟-AGAGTCCAGTCCGATGTC-3‟ 
atg7-Reverse 5‟-GAAGTAACAGCCGAGACG-3‟ 
p62-Forward 5‟-TTTGGCTCTTGTGAAGGATGAC-3‟ 
p62-Reverse 5‟-GAGGGCTAAAGTGAGGTGTAGTGA-3‟ 
mtor-Forward 5‟-ATACGCATCCAGTCCATTG -3‟ 
mtor-Reverse 5‟-TCATTAGCCAGTAGAGTGTTC-3‟ 
lc3b-Forward 5‟-CCTCCAACTCAACTCCAACC-3‟ 
lc3b-Reverse 5‟-GCCGTCTTCGTCTCTTTCC-3‟ 
Housekeeping gene:  
Ef1a-Forward 5‟-CTGTACCTGTGGGTCGTGTGGAGACTG-3‟ 
Ef1a-Reverse 5‟-CAGCCTTCTGTGCAGACTTTGTGAC-3‟ 
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Primary 
antibodies 
Dilution  Company Cat. numb. Lot 
LC3B (NB100-
2220) 
1:500 polyclonal 
 
Novus Biologicals Europe, 
Abingdon, UK 
NB100-2220 
 
Lot:EC 
GAA 1:100 polyclonal 
 
Sigma Aldrich, St. Louis, 
Missouri, USA 
SAB2100872 
 
Lot: QC14285 
p62 1:500 polyclonal 
 
PROGEN Biotechnik GmbH, 
Heidelberg, Germany 
GP62-c 
 
Lot:709151 
mTOR 1:500 polyclonal Santa Cruz Biotecnology, Santa 
Cruz, CA, USA 
sc-8319 
 
N/A* 
p-mTOR 1:200 monoclonal Santa Cruz Biotecnology, Santa 
Cruz, CA, USA 
sc-293133 
 
N/A* 
AMPk 1:500 polyclonal Santa Cruz Biotecnology, Santa 
Cruz, CA, USA 
sc-25792 
 
N/A* 
pAMPk 1:200 polyclonal Santa Cruz Biotecnology, Santa 
Cruz, CA, USA 
sc-33524 
 
N/A* 
BECLIN1 1:500 polyclonal Thermo Fisher, MA, USA PA1-46454 Lot: #SC2360229A 
⍺Tubulin 1:1000 monoclonal Sigma Aldrich, St. Louis, 
Missouri, USA 
T7451 
 
Lot:051M4770 
LAMP2 (H4B4) 1:500 monoclonal DSHB, Iowa, USA 
 
H4B4 
 
N/A 
 
 
Secondary 
antibodies 
Dilution  Company Cat. numb. Lot 
Amersham ECL 
Goat anti-Rabbit 
IgG HRP 
 
1:1000 
 
 
polyclonal 
 
GE Healtcare Lifescience, 
Chicago, IL, USA 
 
 
NA9340V 
 
Lot:16955624 
 
Amersham ECL 
Goat anti-Mouse 
IgG HRP 
 
 
1:1000 
 
 
monoclonal 
 
GE Healtcare Lifescience, 
Chicago, IL, USA 
 
 
NA931V 
 
 
Lot:16982037 
 
Biotin-SP-
conjugated 
AffiniPure Donkey 
Anti-Guinea Pig 
IgG (H+L) 
 
 
1:1000 
 
 
 
 polyclonal 
 
 
Jackson ImmunoResearch, 
Cambridgeshire, UK 
 
 
 
706-065-148 
 
 
 
Lot:106654 
 
 
* kind gift from Dr. Giuseppina Caretti‟s Laboratory, Università degli studi di Milano; 
 
+ Note that, except for the anti-LC3B antibody, validated in zebrafish (see i.e. Ran et al., 2017), all 
other antibodies had not been reported in the literature as cross-reacting with Danio rerio proteins. 
The choice of the right antibody was based on the epitope being at least 40% similar to the 
zebrafish one. 
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HIGHLIGHTS 
 
1) A new transient Pompe disease zebrafish model has been generated and 
characterized; 
 
2) Acid 3-Bromopyruvic (3-BrPA) improves some of defects seen in the PD model; 
 
3) 3-BrPA represents a new promising compound for Pompe disease patients; 
 
4) The zebrafish PD model will simplify testing novel drugs with therapeutic potential. 
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